WO2007063385A3 - Spirocyclic amine histamine-3 receptor antagonists - Google Patents

Spirocyclic amine histamine-3 receptor antagonists Download PDF

Info

Publication number
WO2007063385A3
WO2007063385A3 PCT/IB2006/003355 IB2006003355W WO2007063385A3 WO 2007063385 A3 WO2007063385 A3 WO 2007063385A3 IB 2006003355 W IB2006003355 W IB 2006003355W WO 2007063385 A3 WO2007063385 A3 WO 2007063385A3
Authority
WO
WIPO (PCT)
Prior art keywords
formula
treatment
disorder
compound
disorders
Prior art date
Application number
PCT/IB2006/003355
Other languages
French (fr)
Other versions
WO2007063385A2 (en
Inventor
Mark Leonard Elliott
Harry Ralph Howard Jr
Original Assignee
Pfizer Prod Inc
Mark Leonard Elliott
Harry Ralph Howard Jr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc, Mark Leonard Elliott, Harry Ralph Howard Jr filed Critical Pfizer Prod Inc
Publication of WO2007063385A2 publication Critical patent/WO2007063385A2/en
Publication of WO2007063385A3 publication Critical patent/WO2007063385A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Abstract

This invention is directed to compounds of the formula I as defined herein, or a pharmaceutically acceptable salt thereof; a pharmaceutical composition containing a compound of formula I, a method of treatment of a disorder or condition that may be treated by antagonizing histamine H3 receptors, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above, and a method of treatment of a disorder or condition selected from the group consisting of depression, mood disorders, schizophrenia, anxiety disorders, Alzheimer's disease, attention-deficit disorder (ADD), attention-deficit hyperactivity disorder (ADHD), psychotic disorders, sleep disorders, obesity, dizziness, epilepsy, motion sickness, respiratory diseases, allergy, allergy-induced airway responses, allergic rhinitis, nasal congestion, allergic congestion, congestion, hypotension, cardiovascular disease, diseases of the Gl tract, hyper and hypo motility and acidic secretion of the gastro-intestinal tract, the method comprising administering to a mammal in need of such treatment a compound of formula I as described above.
PCT/IB2006/003355 2005-12-01 2006-11-20 Spirocyclic amine histamine-3 receptor antagonists WO2007063385A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74120705P 2005-12-01 2005-12-01
US60/741,207 2005-12-01

Publications (2)

Publication Number Publication Date
WO2007063385A2 WO2007063385A2 (en) 2007-06-07
WO2007063385A3 true WO2007063385A3 (en) 2007-10-04

Family

ID=38092619

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2006/003355 WO2007063385A2 (en) 2005-12-01 2006-11-20 Spirocyclic amine histamine-3 receptor antagonists

Country Status (1)

Country Link
WO (1) WO2007063385A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9156845B2 (en) 2012-06-29 2015-10-13 Pfizer Inc. 4-(substituted amino)-7H-pyrrolo[2,3-d] pyrimidines as LRRK2 inhibitors

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009082698A1 (en) * 2007-12-21 2009-07-02 Abbott Laboratories Compositions for treatment of cognitive disorders
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
MX2010008375A (en) * 2008-01-30 2011-03-04 Cephalon Inc Star Substituted spirocyclic piperidine derivatives as histamine-3 (h3) receptor ligands.
EA018537B1 (en) 2008-01-30 2013-08-30 Сефалон, Инк. Substituted spirocyclic piperidine derivatives as histamine-3 (h) receptor ligands
ES2602794T3 (en) 2011-03-31 2017-02-22 Pfizer Inc Novel bicyclic pyridinones
WO2012172449A1 (en) 2011-06-13 2012-12-20 Pfizer Inc. Lactams as beta secretase inhibitors
ES2605565T3 (en) 2011-08-31 2017-03-15 Pfizer Inc Hexahydropyran [3,4-D] [1,3] thiazin-2-amine compounds
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
CA2872154C (en) 2012-05-04 2016-08-23 Pfizer Inc. Heterocyclic substituted hexahydropyrano [3,4-d] [1,3] thiazin-2-amine compounds as inhibitors of app, bace1 and bace2
US9260455B2 (en) 2012-09-20 2016-02-16 Pfizer Inc. Alkyl-substituted hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
UA110688C2 (en) 2012-09-21 2016-01-25 Пфайзер Інк. Bicyclic pirydynony
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
EP2931731A1 (en) 2012-12-11 2015-10-21 Pfizer Inc. Hexahydropyrano [3,4-d][1,3]thiazin-2-amine compounds as inhibitors of bace1
WO2014097038A1 (en) 2012-12-19 2014-06-26 Pfizer Inc. CARBOCYCLIC- AND HETEROCYCLIC-SUBSTITUTED HEXAHYDROPYRANO[3,4-d][1,3]THIAZIN-2-AMINE COMPOUNDS
WO2014125394A1 (en) 2013-02-13 2014-08-21 Pfizer Inc. HETEROARYL-SUBSTITUTED HEXAHYDROPYRANO [3,4-d][1,3] THIAZIN-2-AMINE COMPOUNDS
US9233981B1 (en) 2013-02-15 2016-01-12 Pfizer Inc. Substituted phenyl hexahydropyrano[3,4-d][1,3]thiazin-2-amine compounds
CN105121439A (en) 2013-02-19 2015-12-02 辉瑞公司 Azabenzimidazole compounds as inhibitors of pde4 isozymes for the treatment of cns and other disorders
JP6425717B2 (en) 2013-10-04 2018-11-21 ファイザー・インク Novel bicyclic pyridinone as a gamma secretase modulator
JP6487921B2 (en) 2013-12-17 2019-03-20 ファイザー・インク Novel 3,4-disubstituted-1H-pyrrolo [2,3-b] pyridines and 4,5-disubstituted-7H-pyrrolo [2,3-c] pyridazines as LRRK2 inhibitors
SG11201607465UA (en) 2014-04-01 2016-10-28 Pfizer Chromene and 1,1 a,2,7b-tetrahydrocyclopropa[c]chromene pyridopyrazinediones as gamma-secretase modulators
EA030085B1 (en) 2014-04-10 2018-06-29 Пфайзер Инк. 2-AMINO-6-METHYL-4,4a,5,6-TETRAHYDROPYRANO[3,4-d][1,3]THIAZIN-8a(8H)-YL-1,3-THIAZOL-4-YL AMIDES
WO2016012896A1 (en) 2014-07-24 2016-01-28 Pfizer Inc. Pyrazolopyrimidine compounds
AP2017009744A0 (en) 2014-08-06 2017-02-28 Pfizer Imidazopyridazine compounds
JP6628805B2 (en) 2015-02-03 2020-01-15 ファイザー・インク New cyclopropabenzofuranylpyridopyrazinedione
UA125334C2 (en) 2015-06-17 2022-02-23 Пфайзер Інк. Tricyclic compounds and their use as phosphodiesterase inhibitors
RU2722149C1 (en) 2015-09-14 2020-05-27 Пфайзер Инк. New derivatives of imidazo [4,5-c] quinolines and imidazo [4,5-c] [1,5] naphthyridines as lrrk2 inhibitors
JP2018534251A (en) 2015-09-24 2018-11-22 ファイザー・インク N- [2- (3-Amino-2,5-dimethyl-1,1-dioxide-5,6-dihydro-2H-1,2,4-thiadiazin-5-yl) -1 useful as a BACE inhibitor , 3-Thiazol-4-yl] amide
WO2017051303A1 (en) 2015-09-24 2017-03-30 Pfizer Inc. Tetrahydropyrano[3,4-d][1,3]oxazin derivatives and their use as bace inhibitors
AU2016325665A1 (en) 2015-09-24 2018-03-08 Pfizer Inc. N-[2-(2-amino-6,6-disubstituted-4, 4a, 5, 6-tetrahydropyrano [3,4-d][1,3] thiazin-8a (8h)-yl) -1, 3-thiazol-4-yl] amides
US10323042B2 (en) 2016-02-23 2019-06-18 Pfizer Inc. 6,7-dihydro-5H-pyrazolo[5,1-b][1,3]oxazine-2-carboxamide compounds
HUE054857T2 (en) 2016-07-01 2021-10-28 Pfizer 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases
KR102582626B1 (en) 2017-03-10 2023-09-22 화이자 인코포레이티드 Novel imidazo[4,5-C]quinoline derivatives as LRRK2 inhibitors
JP2020514343A (en) 2017-03-10 2020-05-21 ファイザー・インク Cyclic substituted imidazo [4,5-c] quinoline derivative
US20230137562A1 (en) 2017-06-07 2023-05-04 Adrx, Inc. Tau aggregation inhibitors
EP3642202B1 (en) 2017-06-22 2022-11-02 Pfizer Inc. Dihydro-pyrrolo-pyridine derivatives
CA3073062A1 (en) 2017-08-18 2019-02-21 Adrx, Inc. Tau aggregation peptide inhibitors
AR115015A1 (en) 2018-03-23 2020-11-18 Pfizer DERIVATIVES OF AZAESPIRO PIPERAZINE

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0431943A2 (en) * 1989-12-08 1991-06-12 Merck & Co. Inc. Nitrogen-containing spirocycles
EP0518805A1 (en) * 1991-06-13 1992-12-16 H. Lundbeck A/S Piperidine derivatives
WO1996038142A1 (en) * 1995-05-30 1996-12-05 Gliatech, Inc. 1h-4(5)-substituted imidazole derivatives
WO1996039140A1 (en) * 1995-06-06 1996-12-12 Merck & Co., Inc. ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS
WO2000003681A2 (en) * 1998-07-16 2000-01-27 Axys Pharmaceuticals, Inc. Process for the synthesis of benzopyran derivatives
EP0978512A1 (en) * 1998-07-29 2000-02-09 Societe Civile Bioprojet Non-imidazole aryloxy (or arylthio) alkylamines as histamine H3-receptor antagonists and their therapeutic applications
WO2002012224A2 (en) * 2000-08-08 2002-02-14 Ortho Mcneil Pharmaceutical, Inc. Bicyclic compounds as h3 receptor ligands

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0431943A2 (en) * 1989-12-08 1991-06-12 Merck & Co. Inc. Nitrogen-containing spirocycles
EP0518805A1 (en) * 1991-06-13 1992-12-16 H. Lundbeck A/S Piperidine derivatives
WO1996038142A1 (en) * 1995-05-30 1996-12-05 Gliatech, Inc. 1h-4(5)-substituted imidazole derivatives
WO1996039140A1 (en) * 1995-06-06 1996-12-12 Merck & Co., Inc. ALPHA 1a ADRENERGIC RECEPTOR ANTAGONISTS
WO2000003681A2 (en) * 1998-07-16 2000-01-27 Axys Pharmaceuticals, Inc. Process for the synthesis of benzopyran derivatives
EP0978512A1 (en) * 1998-07-29 2000-02-09 Societe Civile Bioprojet Non-imidazole aryloxy (or arylthio) alkylamines as histamine H3-receptor antagonists and their therapeutic applications
WO2002012224A2 (en) * 2000-08-08 2002-02-14 Ortho Mcneil Pharmaceutical, Inc. Bicyclic compounds as h3 receptor ligands

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
YAMATO M ET AL: "SYNTHESIS AND STRUCTURE-ACTIVITY RELATIONSHIP OF SPIRO[ISOCHROMANPIPERIDINE] ANALOGS FOR INHIBITION OF HISTAMINE RELEASE. II", CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, TOKYO, JP, vol. 29, no. 12, 1 December 1981 (1981-12-01), pages 3494 - 3498, XP000651856, ISSN: 0009-2363 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9156845B2 (en) 2012-06-29 2015-10-13 Pfizer Inc. 4-(substituted amino)-7H-pyrrolo[2,3-d] pyrimidines as LRRK2 inhibitors

Also Published As

Publication number Publication date
WO2007063385A2 (en) 2007-06-07

Similar Documents

Publication Publication Date Title
WO2007063385A3 (en) Spirocyclic amine histamine-3 receptor antagonists
UA88719C2 (en) Histamine-3 receptor antagonists
WO2007105053A3 (en) Tetralines antagonists of the h-3 receptor
WO2007138431A3 (en) Azabicyclic ether histamine-3 antagonists
DE602006018301D1 (en) HISTAMINE-3 RECEPTOR ANTAGONISTS
WO2007088450A3 (en) Chromane antagonist of the h-3 receptor
BRPI0513486A (en) substituted 1,3-cycloamino derivatives and their use as histamine-3 receptor antagonists
MX2009007782A (en) Tosylate salt of a therapeutic compound and pharmaceutical compositions thereof.
BRPI0513444A (en) histamine 3 receptor antagonists
MX2007003587A (en) Histamine-3 receptor antagonists.
WO2006024955A8 (en) Azabicyclic amine histamine-3 receptor antagonists
BRPI0507374A (en) histamine-3 receptor modulators
DE502005010170D1 (en) NEW LOW-ACTIVE BETA-2 AGONISTS AND THEIR USE AS DRUGS
MA32898B1 (en) POSITIVE ALLOSTERIC MODULATORS OF ARYLMETHYLBENZOQUINAZOLINONE M1 RECEPTOR
RU2005136535A (en) NEW AZETIDINE COMPOUNDS
EA201001645A1 (en) HINUCLIDINE DERIVATIVES AS ANTAGONISTS OF MUSCARINE M3 RECEPTOR
BRPI0512567A (en) histamine-3 diazabicyclic receptor antagonist compounds and pharmaceutical compositions
EA200600854A1 (en) NEW TIOTROPY SALTS, METHOD OF THEIR PRODUCTION, AND ALSO CONTAINING THEIR MEDICINAL COMPOSITIONS
WO2004030629A3 (en) Novel neurokinin antagonists and methods of use thereof
HUP0400222A2 (en) Composition comprising a pde-4 inhibitor and h1-receptor antagonist and the use thereof for the manufacture of a medicament for the treatment of respiratory diseases
MX2010006162A (en) Tosylate salt of trans-n-isobutyl-3-fluoro-3- [3-flu0r0-4- (pyrrolidin-1-yl-methyl) -phenyl] cyclobut anecarboxamide.
BRPI0816571A2 (en) "compound, process for preparing the compound, pharmaceutical composition, agent and method for treating a disease or disorder of the central nervous system related to or affected by the 5-ht6 receptor"
RU2443697C1 (en) Substituted methyl-amines, serotonin 5-ht6 receptor antagonists, methods of production and use
JP2011518859A5 (en)
CY1114789T1 (en) COMPETITIVES HISTAMIN RECEPTORS-3

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 06820975

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 06820975

Country of ref document: EP

Kind code of ref document: A2